DR. KENNETH TAYLOR RICHARDSON, M.D.
Medical Practice at Switzerland Dr, Anchorage, AK

6429219, Aug 6, 2002

May 3, 2000

09/564070

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Chronorx, LLC - Anchorage AK

A61K 31425

514369, 514494, 514499, 514578

This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.

6693094, Feb 17, 2004

Mar 7, 2002

10/093476

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Chrono RX LLC - Anchorage AK

A61K 31555

514188, 51425506, 514456, 514458, 514494, 514505, 514565, 514593, 514635

The invention describes formulations that include either metformin, sulfonylurea or a biguanide-sulfonylurea combination as one active ingredient in addition to specific, other active ingredients. The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of the included biguanide (metformin) and/or sulfonylurea in the prevention and treatment of insulin resistance and diabetes mellitus. The carefully chosen additional active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and those adverse incidences associated with the concurrent use of metformin and/or the sulfonylureas. When clinically administered, the invention will provide therapeutic levels of metformin and of a sulfonylurea, alone or in combination, and broaden their usefulness. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

6689385, Feb 10, 2004

Nov 2, 2001

10/033730

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

Chronorx LLC - Anchorage AK

A61K 920

424464, 451472, 451482, 451486, 451489

The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

6455061, Sep 24, 2002

Apr 5, 2001

09/828323

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

ChronoRX, LLC - Anchorage AK

A61F 1300

424422, 424427, 424428, 514547, 514574

The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D--tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses. Together the components of this invention provide the potential for improved resistance to, improved recovery from, and a decreased frequency of recurrence of herpes simplex virus infection.

6423847, Jul 23, 2002

Mar 20, 2000

09/532658

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

Chronorx, LLC - Anchorage AK

C07D40500

5462827, 514337

A process of synthesis of D,-tocopherol nicotinate compounds is presented. Therapeutic uses for this compound are described. The active agents are demonstrated to be complementary in their physiological functions especially as these relate to cellular and endothelial biochemistry and physiology and, ultimately to vascular health. The active components of the invention are selected for inclusion in a unique combination that clinically reduces risks of vasculopathy, DNA strand breakage and neuronal excitotoxicity in various diseases. In addition to the systemic vascular benefits acquired, improvement of the vascular health of the eye reduces the risk of glaucomatous optic nerve atrophy with its accompanying visual field loss and potential blindness and reduces conditions of risk for macular degeneration.

2009006, Mar 12, 2009

Nov 10, 2008

12/268244

Kenneth T. Richardson - Anchorage AK, US
Don C. Pearson - Lakewood WA, US
John A. Edwards - Los Altos CA, US

ChronoRX LLC - Anchorage AK

A61K 9/24, A61K 31/4985, A61P 3/10, A61P 3/00, A61P 3/06

424472, 514249

Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease, hearing loss and chronic glaucomas). A novel method for the preparation of TBL is also disclosed.

6231889, May 15, 2001

Sep 15, 1999

9/396019

Kenneth T. Richardson - Anchorage AK
Don C. Pearson - Lakewood WA

ChronoRX, LLC - Anchorage AL

A61K 600, A61K 922, A61K 924, A61F 200, A61F 1300

424464

The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-. alpha. -tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses.

2006019, Aug 31, 2006

Jan 6, 2006

11/326796

Kenneth Richardson - Anchorage AK, US
Don Pearson - Lakewood WA, US
John Edwards - Los Altos CA, US

ChronoRX LLC, an Alaska Limited Liability Company - Anchorage AL

A61K 31/519, A61K 31/385

514250000, 514440000

Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease, hearing loss and chronic glaucomas). A novel method for the preparation of TBL is also disclosed.

4255022, Mar 10, 1981

Oct 2, 1978

5/948115

Christian L. Kuether - Houston TX
Robert E. Williams - Pearland TX
Thomas A. Decker - Houston TX
Charles Kurtzman - Houston TX
Kenneth T. Richardson - Anchorage AK
Richard A. Harrison - Houston TX

Baylor College of Medicine - Houston TX

A61B 306

351 24

A microprocessor based instrument designed to retrofit into existing perimeters utilizing the mechanics and stimulus control aspects of the existing perimeter. The device includes an array board positioned adjacent the perimeter mechanical arm and includes a multiplicity of visual indicators spatially arranged in a composite pattern of testing locations required for one or more ophthalmic testing procedures. A processor is connected to the array board for sequentially actuating the visual indicators in accordance with the testing procedure whereby the operator guides a cursor attached to the perimeter mechanical arm to align with the actuated indicators and control the location of the perimeter test stimulus. The processor includes means for sensing the position of the cursor, silently presenting a light flash to the patient, and a memory which records the patient's responses. When the program test sequence has been completed, the missed locations on the array board actuate allowing the examiner to manually record the data on a printed form.

6288106, Sep 11, 2001

May 3, 2000

9/564074

Don C. Pearson - Lakewood WA
Kenneth T. Richardson - Anchorage AK

ChronoRX, LLC - Anchorage AK

A61K 31385, C07D33902

514440

This invention is in the fields of pharmacology and biochemistry. It relates to processes for the synthesis of certain complexes of. alpha. -lipoic acid and the nutritional or therapeutic use of these and other related individual or complexed antioxidant, proglutathione molecules. Therapeutic uses for these molecules and complexes in the clinical management of conditions and functions associated with chronic glaucoma, insulin resistance, macular degeneration, lenticular cataract, neurodegenerative diseases, essential hypertension, atherosclerosis and vasoconstriction are described in particular.